Peran Toxin Panton-Valentine Leukocidin (PVL) dalam Patogenesis Community-acquired Methicillin-Resistance Staphylococcus aureus (MRSA)

  • Dewi Suryani Fakultas Kedokteran Universitas Mataram

Abstract

Panton-Valentine Leukocidin (PVL) merupakan salah satu gen yang terdapat pada Community Acquired Methicillin-Resistance Staphylococcus aureus (CA-MRSA). Terdapat kontroversi sejauh mana
peran dari PVL dalam menyebabkan konsekunsi klinis yang berat dalam patogenesis CA-MRSA. Ada sebagian peneliti yang setuju bahwa PVL merupakan faktor virulensi utama namun ada sebagian peneliti yang menentang hal ini. Dalam tinjauan pustaka ini akan dibahas mengenai distribusi, struktur dan mekanisme kerja dari PVL positif CA-MRSA. Disamping itu akan dibahas pula mengenai hubungan PVL dengan faktor lain yang berkontribusi terhadap patogenesis penyakit CA-MRSA meliputi: variasi kadar produksi PVL antar strain MRSA, sistem imun host dan gen lain pad CA-MRSA genome yang bekerja bersama PVL dalam menyebabkan penyakit.

References

1. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus PantonValentine leukocidin-induced lung inflammation and injury. Proceedings of the National Academy of Sciences. 2010;107(12):5587–5592.

2. Rasigade JP, Laurent F, Lina G, Meugnier H, Bes M, Vandenesch F, et al. Global distribution and evolution of Panton-Valentine leukocidinpositive methicillin-susceptible Staphylococcus aureus, 1981–2007. The Journal of infectious diseases. 2010;201(10):1589–1597.

3. Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G, et al. Staphylococcus aureus panton-valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS pathogens. 2010;6(1):e1000715.

4. Olsen RJ, Kobayashi SD, Ayeras AA, Ashraf M, Graves SF, Ragasa W, et al. Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates. The American journal of pathology. 2010;176(3):1346–1354.

5. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillinresistant Staphylococcus aureus disease. Journal of Infectious Diseases. 2008;198(8):1166–1170.

6. Varshney AK, Martinez LR, Hamilton SM, Bryant AE, Levi MH, Gialanella P, et al. Augmented production of Panton-Valentine leukocidin toxin in methicillin-resistant and methicillin-susceptible Staphylococcus aureus is associated with worse outcome in a murine skin infection model. The Journal of infectious diseases. 2010;201(1):92–96.

7. Yamamoto T, Nishiyama A, Takano T, Yabe S, Higuchi W, Razvina O, et al. Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance. Journal of Infection and Chemotherapy. 2010;16(4):225–254.

8. Trieu TV, Gaudelus J, Lefevre S, Teychene AM, Poilane I, Colignon A, et al. Sudden death caused by Staphylococcus aureus carrying Panton–Valentine
leukocidin gene in a young girl. BMJ case reports. 2009;2009:bcr0220091542.

9. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine
leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. The Lancet. 2002;359(9308):753–759.

10. Berglund C, Prevost G, Laventie BJ, Keller D, Soderquist B. The genes for Panton Valentine leukocidin (PVL) are conserved in diverse lines of methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Microbes and infection. 2008;10(8):878–884.

11. Tseng CW, Kyme P, Low J, Rocha MA, Alsabeh R, Miller LG, et al. Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS one. 2009;4(7):e6387.

12. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315(5815):1130–1133.

13. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, et al. Presence of genes encoding the Panton-Valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. Journal of clinical microbiology. 2009;47(12):3952–3957.

14. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, et al. Is PantonValentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? The Journal of infectious diseases. 2006;194(12):1761–1770.

15. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proceedings of the
National Academy of Sciences. 2010;107(5):2241–2246.

16. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P, et al. Global distribution of PantonValentine leukocidin–positive methicillin-resistant
Staphylococcus aureus, 2006. Emerging infectious diseases. 2007;13(4):594.

17. Tong SY, Lilliebridge RA, Bishop EJ, Cheng AC, Holt DC, McDonald MI, et al. Clinical correlates of Panton-Valentine leukocidin (PVL), PVL isoforms,
and clonal complex in the Staphylococcus aureus population of Northern Australia. The Journal of infectious diseases. 2010;202(5):760–769.

18. Enany S, Yaoita E, Yoshida Y, Enany M, Yamamoto T. Molecular characterization of Panton-Valentine leukocidin-positive communityacquired methicillin-resistant Staphylococcus aureus isolates in Egypt. Microbiological research. 2010;165(2):152–162.

19. Monecke S, Ehricht R, Slickers P, Tan HL, Coombs G. The molecular epidemiology and evolution of the Panton–Valentine leukocidin-positive, methicillin-resistant Staphylococcus aureus strain USA300 in Western Australia. Clinical Microbiology and Infection. 2009;15(8):770–776.

20. Boakes E, Kearns A, Ganner M, Perry C, Warner M, Hill R, et al. Molecular diversity within clonal complex 22 methicillin-resistant Staphylococcus
aureus encoding Panton–Valentine leukocidin in England and Wales. Clinical Microbiology and Infection. 2011;17(2):140–145.

21. Aman MJ, Karauzum H, Bowden MG, Nguyen TL. Structural model of the pre-pore ring-like structure of Panton-Valentine leukocidin: providing dimensionality to biophysical and mutational data. Journal of Biomolecular Structure and Dynamics. 2010;28(1):1–12.

22. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al. Complete genome sequence of USA300, an epidemic clone of community acquired meticillin-resistant Staphylococcus aureus. The Lancet. 2006;367(9512):731–739.

23. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, et al. Evolution of virulence in epidemic community-associated methicillin-resistant
Staphylococcus aureus. Proceedings of the National Academy of Sciences. 2009;106(14):5883–5888.

24. Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K. Phenol-soluble modulin α3 enhances the human neutrophil lysis mediated by PantonValentine leukocidin. The Journal of infectious diseases. 2009;200(5):715–723.

25. Kobayashi SD, DeLeo FR. An update on community-associated MRSA virulence. Current opinion in pharmacology. 2009;9(5):545–551.

26. Brown E, Dumitrescu O, Thomas D, Badiou C, Koers E, Choudhury P, et al. The Panton–Valentine leukocidin vaccine protects mice against lung and
skin infections caused by Staphylococcus aureus USA300. Clinical Microbiology and Infection. 2009;15(2):156–164.

27. Gonzalez BE, Hulten KG, Dishop MK, Lamberth LB, Hammerman WA, Mason Jr EO, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clinical infectious diseases. 2005;41(5):583–590.

28. DeLeo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infectious disease clinics of North America. 2009;23(1):17–34.

29. des Horts TB, Dumitrescu O, Badiou C, Thomas D, Benito Y, Etienne J, et al. A histidine-to-arginine substitution in Panton-Valentine leukocidin from
USA300 community-acquired methicillin-resistant Staphylococcus aureus does not impair its leukotoxicity. Infection and immunity. 2010;78(1):260–264.

30. Saıd-Salim B, Mathema B, Braughton K, Davis S, Sinsimer D, Eisner W, et al. Differential distribution and expression of Panton-Valentine leucocidin
among community-acquired methicillin-resistant Staphylococcus aureus strains. Journal of clinical microbiology. 2005;43(7):3373–3379.

31. des Horts TB, Dumitrescu O, Badiou C, Thomas D, Benito Y, Etienne J, et al. A histidine to arginine substitution in Panton-Valentin leukocidin from
USA300 CA-MRSA does not impair its leukotoxicity. Infection and Immunity. 2009;.

32. Graves SF, Kobayashi SD, DeLeo FR. Communityassociated methicillin-resistant Staphylococcus aureus immune evasion and virulence. Journal of
molecular medicine. 2010;88(2):109–114.

33. Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert opinion on biological therapy. 2010;10(7):1049–1059.
Published
2018-02-27
Section
Literature Review

Most read articles by the same author(s)